Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).Benjamin Levy, Myung‐Ju Ahn, Christina S. Baik et al.|Journal of Clinical Oncology|2025Cited by 4
Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih‐Hsin Yang, Jonathan W. Riess, Yuh‐Min Chen et al.|Clinical Lung Cancer|2025Cited by 3